- United States
- /
- Electrical
- /
- NYSE:GEV
A Look At GE Vernova (GEV) Valuation After Earnings Beat And Raised 2026 Guidance
GE Vernova (GEV) is back in focus after its first quarter 2026 earnings, where revenue reached US$9,339 million and net income was US$4,745 million, alongside higher full year guidance.
See our latest analysis for GE Vernova.
GE Vernova’s share price has cooled in the very short term, with a 1-day share price return of a 1.89% decline and a 7-day share price return of a 7.50% decline. However, the 30-day and year-to-date share price returns of 18.29% and 56.42% respectively, alongside a 1-year total shareholder return of 168.79%, point to strong momentum built around its earnings beat, raised guidance, AI driven power demand narrative and ongoing buyback activity.
If you are looking beyond a single stock in the electrification and power grid theme, this is a good moment to check out 35 power grid technology and infrastructure stocks
After such a strong run, combined with upbeat guidance and analyst optimism, the key question for you is this: Is GE Vernova still undervalued, or is the stock already pricing in years of future growth?
Most Popular Narrative: 9.5% Undervalued
GE Vernova’s last close of $1,062.95 sits below a narrative fair value of $1,174.89, which presents the stock as undervalued at today’s price.
Revenue Growth: GE Vernova is expected to grow its revenue by 13%, contributing to a total revenue of US$77 billion.
Read the complete narrative. Read the complete narrative.
Curious what underpins that higher fair value per share? The narrative focuses on expanding revenue, rising earnings and a punchy profit multiple. Interested in how those ingredients combine into the final valuation assessment.
Result: Fair Value of $1,174.89 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are clear risks, including execution missteps across Power, Wind and Electrification, or lower than expected earnings that would challenge such an optimistic price-to-earnings based narrative.
Find out about the key risks to this GE Vernova narrative.
Another View: Our DCF Model Flags Overvaluation
That upbeat narrative fair value of $1,174.89 contrasts with the SWS DCF model, which puts GE Vernova’s future cash flow value at $845.68 per share. On this view, the current $1,062.95 price looks expensive, not cheap. This raises a simple question for you: are earnings and cash flow forecasts too cautious, or is the narrative multiple too generous?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out GE Vernova for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
After weighing these mixed signals, do you feel the stock is leaning more toward opportunity or risk, and how quickly do you want to decide? To pressure test your own view against the current mix of concerns and optimism, take a closer look at the 4 key rewards and 2 important warning signs
Looking for more investment ideas?
If GE Vernova has sharpened your interest, do not stop here. Use the Simply Wall St Screener to widen your watchlist and clarify your next move.
- Target long term compounding potential by scanning for 51 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect their balance sheets and cash flows.
- Prioritise resilience by focusing on 71 resilient stocks with low risk scores that score well on financial health metrics and show lower historical risk indicators.
- Hunt for underfollowed opportunities by reviewing screener containing 25 high quality undiscovered gems that still show strong fundamentals despite limited market attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Moderna nearly tripled overnight, and every other mRNA stock jumped with it. I think that could be a trap.

Happy for the melanoma patients. It is no surprise that other companies moved up too. It's the optionality getting priced in.
There’s a 60% to 85% probability of the vaccine being approved based on historical drug development data. Could be a lot of scrutiny by the FDA due to the novel platform used.
Market might be getting a little ahead of itself here.
About NYSE:GEV
GE Vernova
An energy company, engages in the provision of various products and services that generate, transfer, orchestrate, convert, and store electricity in the United States, Europe, Asia, the Middle East, and Africa.
Solid track record and good value.